BridgeBio Oncology Therapeutics, Inc. · NASDAQ:BBOT

BridgeBio Oncology Therapeutics, Inc. financial statements

BridgeBio Oncology Therapeutics, Inc.'s income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021
Revenue000
Cost of revenue610.0K
Gross profit-610.0K
Research and development121.2M73.1M56.3M
Selling, general and administrative24.6M7.76M8.48M3.52K74.3K
Operating income-145.8M-80.9M-41.7K-3.52K-43.4K
Depreciation and amortization280.0K208.0K92.0K3.52K74.3K
EBITDA-145.5M-80.7M50.3K031.0K
Income before tax-134.0M-74.3M-64.7M-3.52K-43.4K
Income tax00
Net income-134.0M-74.3M-41.7K-3.52K-43.4K
Earnings per share, basic-4.30-5,756.41-0.00-0.00-0.00
Earnings per share, diluted-4.30-5,756.41

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021
Cash and equivalents373.7M30.9M0
Short-term investments51.8M124.8M0
Receivables386.0K
Current assets432.4M158.7M3.94M
Property, plant and equipment956.0K490.0K
Total assets448.4M164.3M332.9K144.6K144.3K
Accounts payable1.37M3.07M575.0K
Current liabilities35.0M19.6M396.5K166.5K162.6K
Total debt2.77M70.1K43.1K37.0K
Total liabilities37.3M19.6M396.5K166.5K162.6K
Shareholders' equity411.1M-178.6M-115.6M-21.9K-18.4K
Shares outstanding80.0M28.4K80.0M20.5M20.5M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021
Cash from operations-113.9M-55.0M-52.1M
Capital spending-606.0K-49.0K-414.0K00
Free cash flow-114.5M-55.1M-52.5M
Cash from investing73.3M-120.5M-2.82M
Cash from financing383.4M206.3M55.1M
Change in cash342.8M30.7M225.0K